Recent Investment Analysts’ Ratings Updates for Charles River Laboratories International (CRL)

Posted by Carolyn Dwyer on Mar 6th, 2025

Charles River Laboratories International (NYSE: CRL) has recently received a number of price target changes and ratings updates:

3/4/2025 – Charles River Laboratories International was upgraded by analysts at Citigroup Inc. from a “sell” rating to a “neutral” rating. They now have a $175.00 price target on the stock, up previously from $155.00.
3/3/2025 – Charles River Laboratories International was upgraded by analysts at Redburn Atlantic from a “sell” rating to a “neutral” rating. They now have a $188.00 price target on the stock.
2/20/2025 – Charles River Laboratories International had its price target lowered by analysts at JPMorgan Chase & Co. from $175.00 to $165.00. They now have a “neutral” rating on the stock.
2/20/2025 – Charles River Laboratories International had its price target lowered by analysts at Robert W. Baird from $177.00 to $173.00. They now have a “neutral” rating on the stock.
2/18/2025 – Charles River Laboratories International had its price target lowered by analysts at Barclays PLC from $205.00 to $166.00. They now have an “equal weight” rating on the stock.
2/5/2025 – Charles River Laboratories International had its price target lowered by analysts at Morgan Stanley from $220.00 to $184.00. They now have an “equal weight” rating on the stock.
2/3/2025 – Charles River Laboratories International had its price target lowered by analysts at JPMorgan Chase & Co. from $215.00 to $175.00. They now have a “neutral” rating on the stock.
1/23/2025 – Charles River Laboratories International had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $220.00 to $190.00. They now have a “buy” rating on the stock.
1/22/2025 – Charles River Laboratories International was downgraded by analysts at William Blair from an “outperform” rating to a “market perform” rating.
1/17/2025 – Charles River Laboratories International had its “neutral” rating reaffirmed by analysts at UBS Group AG. They now have a $185.00 price target on the stock, down previously from $250.00.
1/14/2025 – Charles River Laboratories International had its “outperform” rating reaffirmed by analysts at William Blair.

Charles River Laboratories International Stock Performance

Shares of CRL stock traded up $1.15 during trading on Thursday, reaching $168.70. 161,194 shares of the company’s stock were exchanged, compared to its average volume of 692,459. The stock has a market capitalization of $8.63 billion, a PE ratio of 1,124.63, a PEG ratio of 4.54 and a beta of 1.45. The firm’s fifty day moving average price is $170.06 and its 200-day moving average price is $186.32. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same period in the prior year, the firm posted $2.46 EPS. The company’s revenue for the quarter was down 1.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Buying and Selling

In related news, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Charles River Laboratories International

A number of large investors have recently modified their holdings of CRL. Versant Capital Management Inc lifted its holdings in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares during the last quarter. Assetmark Inc. increased its position in Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. lifted its stake in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the last quarter. Optiver Holding B.V. bought a new position in Charles River Laboratories International in the 4th quarter valued at approximately $37,000. Finally, GeoWealth Management LLC boosted its position in Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock valued at $46,000 after buying an additional 190 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).